| Literature DB >> 32545484 |
Fábio C Coelho1, Rosanna Squitti2, Mariacarla Ventriglia3, Giselle Cerchiaro4, João P Daher5, Jaídson G Rocha1, Mauro C A Rongioletti6, Anna-Camilla Moonen7.
Abstract
Copper is an essential nutrient for plants, animals, and humans because it is an indispensable component of several essential proteins and either lack or excess are harmful to human health. Recent studies revealed that the breakdown of the regulation of copper homeostasis could be associated with Alzheimer's disease (AD), the most common form of dementia. Copper accumulation occurs in human aging and is thought to increase the risk of AD for individuals with a susceptibility to copper exposure. This review reports that one of the leading causes of copper accumulation in the environment and the human food chain is its use in agriculture as a plant protection product against numerous diseases, especially in organic production. In the past two decades, some countries and the EU have invested in research to reduce the reliance on copper. However, no single alternative able to replace copper has been identified. We suggest that agroecological approaches are urgently needed to design crop protection strategies based on the complementary actions of the wide variety of crop protection tools for disease control.Entities:
Keywords: agroecology; dementia; heavy metal; organic agriculture
Mesh:
Substances:
Year: 2020 PMID: 32545484 PMCID: PMC7356523 DOI: 10.3390/biom10060897
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Pie chart illustrating the literature published on the topic ‘Copper’ and “Alzheimer’s disease”. Search on the Scopus research engine retrieved 3009 scientific articles; the stratification by ‘subject area’ reveals that 25.7% of the papers published come from the Biochemistry area, 17.3% from Medicine, 15.8% from Neuroscience, 12.7% from Chemistry and 9.2% from Pharmacology.
Clinical studies analyzing the copper and ATP7B link to Alzheimer’s disease risk and the association with the subjects’ clinical status.
| Subjects | Risk (OR 1, RR 2, HR 3) | CI 4 95% | ||
|---|---|---|---|---|
|
| ||||
| Copper level was higher in subjects with AD than in control subjects and correlated with poor neuropsychological performance and medial temporal lobe atrophy [ | 76 AD vs. 79 healthy subjects | 1.8 | 1.36–2.43 | |
| Copper level was higher in subjects with AD than in patients with vascular dementia subjects (VaD) [ | 48 AD vs. 20 VaD | 2.06 | 1.28–3.31 | |
| Non-ceruloplasmin copper was higher in AD than in healthy controls and VaD and correlated with poor neuropsychological performance [ | 47 AD vs. 44 healthy subjects and 24 VaD subjects | |||
| Non-ceruloplasmin copper was higher in AD than in healthy controls; Cerebrospinal (CSF) β-amyloid and H-Tau correlated with serum non-ceruloplasmin copper; copper in the CSF was partially dependent on the serum Non-ceruloplasmin copper (t = 2.2, | 28 AD vs. 25 healthy subjects | |||
| Non-ceruloplasmin copper predicted the annual change in MMSE; when the annual change in MMSE was divided into <3 or ≥3 points, Non-ceruloplasmin copper was the only predictor of a more severe decline [ | 81 AD subjects, 1 year longitudinal study | 1.23 | 1.03–1.47 | |
| Non-ceruloplasmin copper was higher in MCI than in healthy subjects [ | 83 MCI subjects, 100 healthy subjects | 1.22 | 1.05–1.41 | |
| Copper level showed a significant increase in the serum of AD and MCI compared to control ( | 36 AD, 18 MCI vs. 25 healthy subjects | |||
| Non-ceruloplasmin copper increased the risk of having AD; when combined in an algorithm with sex, APOE, Cp/Tf, TAS, the ability to discriminate AD patients vs. controls was high (ROC 5, AUC 6 = 0.9) [ | 93 AD, 45 VaD, 48 healthy subjects | 3.21 | 1.53–6.71 | |
| Non-ceruloplasmin copper was a predictor of conversion to AD: MCI subjects with nonceruloplasmin-Cu levels > 1.6 µmol/L had a hazard conversion rate (50% conversion in 4 years) that was ~3 higher than those with values ≤ 1.6 µmol/L (< 20% in 4 years) [ | 131 MCI subjects, 6 years longitudinal study | 3.3 | 1.21–9.24 | |
| Non-ceruloplasmin copper levels higher in MCI and AD with respect to control ( | 44 AD and 36 MCI vs. 28 healthy subjects | |||
| Non-ceruloplasmin copper and Cu:Cp resulted higher in AD and in Wilson disease (WD) than in healthy controls; while nCp-Cu was similar between AD and WD, Cu:Cp was higher in WD. 24 h urinary copper excretion in AD patients (12.05 μg/day) was higher than in healthy controls (4.82 μg/day); 77.8% of the AD patients under D-penicillamine treatment had a 24 h urinary excretion higher than 200 μg/day, suggestive of a failure of copper control [ | 385 AD, 9 WD, 336 healthy subjects | |||
| Non-ceruloplasmin copper does not change in frontotemporal lobar degeneration (FTLD) [ | 85 FTLD, 55 healthy subjects | |||
|
| ||||
| Specific genetic variants in the | 285 AD vs. 230 healthy subjects | 2.3 | 1.41–3.77 | |
| Wilson disease-causing variant rs7334118 in linkage disequilibrium with the intronic rs2147363 (associated with AD risk) was detected in two AD patients but in no healthy individuals. However, this Wilson disease mutation did not explain the observed genetic association of rs2147363. Conversely, in silico analyses of rs2147363 functionality highlighted that this variant is located in a binding site of a transcription factor and is associated with regulatory functions [ | 286 AD vs. 283 healthy subjects | 1.3 | 1.06–1.69 | |
| Haplotype TGC in specific genetic variants in the | 120 AD vs. 111 healthy subjects | 5.16 | 2.54–10.5 |
1 OR, odds ratio; 2 RR, relative risk; 3 HR, hazard ratio; 4 CI, Coefficient Interval; 5 ROC, receiver operating characteristic curves depict the likelihood of a given test to be excellent, good, or worthless. The accuracy of the test depends, in this case, on the probability that a subject randomly selected from AD group has a nonceruloplasmin copper value higher than that of a subject randomly selected from the healthy control group. The accuracy is measured by the 6 AUC (area under the curve) of the ROC curve. An AUC = 1 represents a perfect test, a value of 0.5 represents a worthless test, and values in the 0.7–0.8 range are considered to be fair.
Experimental models focused on the investigation of the causative correlation of copper and non-ceruloplasmin copper in Alzheimer’s disease (AD) development and progression.
| Authors, Year | Animal Model | Dose and Route | Duration | Effects |
|---|---|---|---|---|
|
| ||||
| Sparks and Schreurs, 2003 [ | New Zealand white rabbits | 12 mg/L copper in DW 1 + 2% cholesterol − oral | 10 weeks | Accumulation of Aβ in brain; deficit in complex memory acquisition |
| Sparks et al., 2006 [ | Beagle dogs | 200 mg/L CuSO4 in DW + high fat diet − oral | 4 months | Extracellular Aβ deposits |
| Lu et al., 2006 [ | Kumming strain mice | 0.21 mg/L copper in DW + 2% cholesterol − oral | 8 weeks | Cognitive deficits; neuronal apoptosis |
| Arnal et al., 2013 [ | Wistar rat | 3 mg/L copper in tap water + 2% cholesterol − oral | 2 months | Increased oxidative stress in brain; increased non-ceruloplasmin copper in hippocampus; increased Aβ (1–42)/ Aβ (1–40) in cortex and hippocampus |
| Arnal et al., 2013 [ | Wistar rat | 3 mg/L copper in tap water + 2% cholesterol − oral | 8 weeks | Slight nut noticeable change in visuo-spatial memory |
| Yao et al., 2018 [ | Tg2567 mouse | 0.1 mg/L copper in drinking water and 2% cholesterol in the food | 3 months | Significant deposit of Aβ and senile-plaque formation in hippocampus and temporal cortex regions |
| Abolaji et al., 2020 [ | D. melanogaster flies | Cu2+ (1 mM) | 7 days | reduced survival |
| Lamtai et al., 2020 [ | Rat | CuCl2 (0.25 mg/kg, 0.5 mg/kg and 1 mg/kg) injected intraperitoneally | 8 weeks | Working memory, spatial learning and memory were significantly impaired in rats treated with Cu at dose of 1 mg/kg |
|
| ||||
| Sparks et al., 2006 [ | Watanable rabbits | 0.13 mg/L copper in DW − oral | 10 weeks | Accumulation of Aβ in superior temporal cortex and hippocampus |
| Sparks et al., 2006 [ | PS1/APP transgenic mice | 0.12 mg/L Cu in DW − oral | 6 weeks | Deposition of Aβ |
| Singh et al., 2013 [ | APP sw/0 mice | 0.13 mg/L copper in DW − oral | 90 days | Increase brain Aβ production; increased neuroinflammation; memory impairment; increased Cu levels in brain capillaries and parenchyma |
| Yu et al., 2014 [ | 3xTg-AD | 250 mg/L CuSO4 in drinking water | 6 months | memory impairment |
1 DW, deionized water.